Inactive Instrument

News Lannett Company, Inc.

Stocks

LCI

US5160122009

Pharmaceuticals

All News

05-29	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination	CI
05-19	FDA Approves Lannett, Lanexa Biologics, And Sunshine Lake Pharma’s Interchangeable Insulin Glargine Biosimilar	AQ
25-07-29	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.	CI
23-06-16	Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	CI
23-06-16	Lannett Company, Inc. Emerged from Bankruptcy	CI
23-06-08	First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	CI
23-06-05	First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	CI
23-05-15	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-05-04	Motion for Joint Administration Approved for Lannett Company, Inc.	CI
23-05-04	Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	CI
23-05-03	Motion for Joint Administration Filed by Lannett Company, Inc.	CI
23-05-02	LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION	PR
23-05-02	Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	CI
23-05-02	Lannett Company, Inc. Filed for Bankruptcy	CI
23-05-01	Lannett Company, Inc. Enters Into Restructuring Support Agreement	PR
23-04-25	Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	CI
23-04-20	NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS	PR
23-04-14	LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	CI
23-04-14	John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	CI
23-04-04	LANNETT CO INC : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-04-04	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	CI
23-04-04	LANNETT SHARES UPDATE	PR
23-02-07	Lannett : Modification to Rights of Security Holders - Form 8-K	PU
23-02-07	LANNETT CO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ